A single-arm, single-center phase II trial study to assess the efficacy and safety of disitamab vedotin plus cadonilimab as first-line therapy for HER2-overexpressing advanced stomach carcinoma
Age: more than 18 years, gender is not limited;
Confirmed locally advanced or distant metastasis gastric or gastroesophageal junction adenocarcinoma that is inoperable by pathological examination;
Confirmed HER2 2+or 3+ by immunohistochemistry (IHC);
At least 1 measurable lesion as determined by RECIST 1.1;
Allergy to any trial drug and its excipients, or serious allergy history, or contraindication of the trial drugs;
NYHA grade 2 or above heart failure;
Unstable angina pectoris;
Myocardial infarction occurred within 12 months;